Ramaco’s CEO said that, with $600 million-plus (before fees) in capital raises in the second half of 2025, the firm is well-positioned to pursue opportunities to unlock value and maximize shareholder returns.
With the new deal, Merck would gain access to CD388, currently in late-stage development, and designed to prevent influenza infection in individuals at higher risk of influenza complications.
Toyota now expects a 1.4 trillion yen impact from U.S. tariffs for fiscal year 2026, a 1.2 trillion yen increase from the effect reflected in the previous forecast.